Page 130 - 2021_04-Haematologica-web

R.S. Mali et al.
Molecular patterns of response and treat-
ment failure after frontline venetoclax com- binations in older patients with AML. Blood. 2020;135(11):791-803.
22. Fulda S. Modulation of mitochondrial apop- tosis by PI3K inhibitors. Mitochondrion. 2013;13(3):195-198.
23. Thomas LW, Lam C, Edwards SW. Mcl-1; the molecular regulation of protein function. FEBS Lett. 2010;584(14):2981-2989.
24. Grad JM, Zeng X-R, Boise LH. Regulation of Bcl-XL: a little bit of this and a little bit of STAT. Curr Opin Oncol. 2000;12(6):543-549.
25. Alvarez J, Frank D. Genome-wide analysis of STAT target genes: elucidating the mech- anism of STAT-mediated oncogenesis. Cancer Biol Ther. 2004;3(11):1045-1050.
26. Yoshimoto G, Miyamoto T, Jabbarzadeh- Tabrizi S, et al. FLT3-ITD up-regulates MCL- 1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation. Blood. 2009; 114(24):5034-5043.
27. Minami Y, Yamamoto K, Kiyoi H, Ueda R, Saito H, Naoe T. Different antiapoptotic pathways between wild-type and mutated FLT3: insights into therapeutic targets in leukemia. Blood. 2003;102(8):2969-2975.
28. Spiekermann K, Dirschinger RJ, Schwab R, et al. The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3. Blood. 2003;101(4):1494-1504.
29. Kasper S, Breitenbuecher F, Heidel F, et al. Targeting MCL-1 sensitizes FLT3-ITD-posi- tive leukemias to cytotoxic therapies. Blood Cancer J. 2012;2(3):e60.
30.Bagrintseva K, Geisenhof S, Kern R, et al. FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overex- pression of Bcl-x(L). Blood. 2005; 105(9):3679-3685.
31. Ma J, Zhao S, Qiao X, et al. Inhibition of Bcl- 2 synergistically enhances the antileukemic activity of midostaurin and gilteritinib in preclinical models of FLT3-mutated acute
myeloid leukemia. Clin Cancer Res. 2019;
25(22):6815-6826.
32. Zarrinkar PP, Gunawardane RN, Cramer
MD, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood. 2009;114(14):2984-2992.
33. Levis MJ, Cortes JE, Gammon GM, Trone D, Kang D, Li J. Laboratory and clinical investi- gations to identify optimal dosing strategy for quizartinib (AC220) monotherapy in FLT3-ITD positive relapsed/refractory acute myeloid leukemia. Blood. 2016; 128(22): 4042.
34. Foucquier J, Guedj M. Analysis of drug com- binations: current methodological land- scape. Pharmacol Res Perspect. 2015; 3(3):e00149.
35. Yang T, Kozopas KM, Craig RW. The intra- cellular distribution and pattern of Mcl-1 overlap with, but are not identical to, those of Bcl-2. J Cell Biol. 1995;128(6):1173-1184.
36. Rooswinkel RW, van de Kooij B, de Vries E, et al. Antiapoptotic potency of Bcl-2 pro- teins primarily relies on their stability, not binding selectivity. Blood. 2014; 123(18): 2806-2815.
37. Del Gaizo Moore V, Letai A. BH3 profiling-- measuring integrated function of the mito- chondrial apoptotic pathway to predict cell fate decisions. Cancer Lett. 2013;332(2):202- 205.
38. Sonoyama J, Matsumura I, Ezoe S, et al. Functional cooperation among Ras, STAT5, and phosphatidylinositol 3-kinase is required for full oncogenic activities of BCR/ABL in K562 cells. J Biol Chem. 2002; 277(10):8076-8082.
39.Smith CC, Wang Q, Chin CS, et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature. 2012;485(7397):260-263.
40. McMahon CM, Ferng T, Canaani J, et al. Clonal selection with RAS pathway activa- tion mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia. Cancer Discov. 2019;9(8):1050- 1063.
41. Naqvi K, Konopleva M, Ravandi F. Targeted therapies in acute myeloid leukemia: a focus on FLT-3 inhibitors and ABT199. Expert Rev Hematol. 2017;10(10):863-874.
42. Blombery P, Anderson MA, Gong J-n, et al. Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia. Cancer Discov. 2019;9(3):342-353.
43. Tausch E, Close W, Dolnik A, et al. Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia. Haematologica. 2019;104(9):434-437.
44. Pratz KW, Sato T, Murphy KM, Stine A, Rajkhowa T, Levis M. FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. Blood. 2010;115(7):1425-1432.
45. Loghavi S, Zuo Z, Ravandi F, et al. Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations. J Hematol Oncol. 2014;7:74.
46. Bezerra MF, Lima AS, Piqué-Borràs M-R, et al. Co-occurrence of DNMT3A, NPM1, FLT3 mutations identifies a subset of acute myeloid leukemia with adverse prognosis. Blood. 2020;135(11):870-875.
47. Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381(18):1728-1740.
48. Karjalainen R, Pemovska T, Popa M, et al. JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell- induced protection of AML. Blood. 2017; 130(6):789-802.
49.Niu X, Wang G, Wang Y, et al. Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocyt- ic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199. Leukemia. 2014;28(7):1557-1560.
50.
Perl AE, Daver NG, Pratz KW, et al. Venetoclax in combination with gilteritinib in patients with relapsed/refractory acute myeloid leukemia: a Phase 1b study. Blood. 2019;134(Supp_1):3910.
1046
haematologica | 2021; 106(4)